City
Epaper

DRDO's anti-COVID 2-DG drug effective against different variants: DRDO scientists

By ANI | Updated: May 8, 2021 19:40 IST

The Defence Research and Development Organisation (DRDO)'s new anti-COVID drug, just approved by the Drugs Controller General of India (DCGI) is effective against different variants of the coronavirus and helps in bringing patients out of oxygen support, said DRDO scientists.

Open in App

The Defence Research and Development Organisation (DRDO)'s new anti-COVID drug, just approved by the Drugs Controller General of India (DCGI) is effective against different variants of the coronavirus and helps in bringing patients out of oxygen support, said DRDO scientists.

Dr Anant Narayan Bhatt, a scientist at the DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) while speaking tosaid, "In the Phase 3 trials for 2-deoxy-D-glucose (2-DG), a large number of patients were tested and it was found that many patients are coming out of oxygen (support)... The mechanism of action is very unique and as per the basics principles of this drug, it will be very effective on different variants of the SARS-CoV-2 virus."

The DCGI approved the emergency use of the 2-deoxy-D-glucose earlier in the day, as an adjunct therapy in moderate to severe COVID-19 cases.

"Based on the successful phase 3 trials, the DCGI has given us emergency use authorization," Bhatt added.

Work on the new drug started in April last year, informed Dr Sudhir Chandna, another senior scientist at INMAS-DRDO and have shown very promising results.

"In April last year, we had started very important work for the COVID-19 drug. This is a molecule called 2-deoxy-D-glucose. Testing had started last year. The first experiment was conducted in CCMB Hyderabad where the effect of the drug on the virus was studied. That showed excellent results," Chandna told ANI.

He added that after permission from the DCGI, phase 2 clinical trials started in May 2020 till October.

"We saw very good results. COVID patients benefited from taking the medicine. After that phase 3 trials started," he said.

In a statement, the DRDO informed that clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.

A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from Covid-19 in the ongoing pandemic, it added.

This comes as a promising development amid the devastating second wave of the COVID-19 pandemic, which has brought the country's healthcare infrastructure to its knees.

In the last 24 hours, as many India reported as many as 4,01,078 new COVID-19 cases, 3,18,609 discharges, and 4,187 deaths, as per Union Health Ministry.

The total cases now stand at 2,18,92,676, including 1,79,30,960 recoveries, 2,38,270 deaths and 37,23,446 active cases.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Sudhir ChandnaindiaHyderabadDrdoDefence Research And Development OrganisationNagarDefence research & development organisationHyderIndiUk-indiaThe directorate for defense research and development
Open in App

Related Stories

OpinionsWhy is Trump So Upset with India?

MumbaiUniversity of Bristol Chooses Mumbai for Its First Overseas Campus, Set to Open in September 2026

NationalOdisha: DRDO Successfully Conducts Two Consecutive Flight-Tests of Pralay Missile

NationalRaksha Bandhan 2025: Now You Can Send a Rakhi to Your Brother in India Post's Waterproof Envelope — Here's How to Track Your Parcel

NationalGold in Dubai Cheaper Than India: Pricing, Rules, and Import Limits Explained

National Realted Stories

NationalKarti Chidambaram backs India's firm rebuttal to Trump's tariff move

NationalOdisha to set up 835 model primary schools in first phase of flagship scheme

NationalHow US encouraged India to buy Russian oil to stabilise global energy markets

NationalDelhi Crime: Girl Shot Dead Inside Doctor’s Clinic in Jahangirpuri; Attacker on the Run

NationalCong's Manish Tewari invokes 1971 to counter US tariff move on India